Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches.

about

Does ketamine have anti-suicidal properties? Current status and future directions Inflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment.KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT?

P2860

Q35235620-DF53FCBE-7900-4379-8F90-8CF72B791C87 Q37310533-9B4051DA-DD07-49C8-9EC0-3CDB315FD338 Q38809056-06477AB5-298A-49D6-B455-EFBDFDCFDFB2

P2860

Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches.

Item

http://www.wikidata.org/entity/Q38573810

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches.

@en

type

Item

label

Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches.

@en

prefLabel

Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches.

@en

P1476

Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches.

@en

P2093

Alan Swann

http://www.w3.org/2001/XMLSchema#string

Rayan K Al Jurdi

http://www.w3.org/2001/XMLSchema#string

Sanjay J Mathew

http://www.w3.org/2001/XMLSchema#string

P2860

Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis

Two-Year Randomized Controlled Trial and Follow-up of Dialectical Behavior Therapy vs Therapy by Experts for Suicidal Behaviors and Borderline Personality Disorder

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report

Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial

Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)

Antidepressant effects of ketamine in depressed patients

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies.

(R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function.

P2888

s11920-015-0614-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11920-015-0614-9

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1044291743

http://www.w3.org/2001/XMLSchema#string

P698

26307033

http://www.w3.org/2001/XMLSchema#string

P921

Bunuh diri

suicide risk

Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches.

about

P2860

P2860

Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698

P921